Global Coronavirus (COVID-19) Current Therapy Market Report 2024

COVID-19 (COVID-19) Current Therapy Global Market Report 2024 – By Drug Type (Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others), By Route Of Administration (Oral, Intravenous), By End-User (Hospitals, Clinics, Home Care, Others) – Market Size, Trends, And Global Forecast 2024-2035

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Coronavirus (COVID-19) Current Therapy Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

COVID-19 (COVID-19) Current Therapy Market Definition And Segments

COVID-19 (COVID-19) current therapy refers to a drug created and used to treat mild to moderate COVID-19 in those who have a higher risk of experiencing significant illness as a result of COVID-19.

The main types of drugs in COVID-19 (COVID-19) current therapy are antiviral, monoclonal antibodies, corticosteroids, supplements, antimalarial, interferons and interleukin inhibitors, other anti-infective drugs, and others. Antivirals are a class of medications or substances designed to inhibit the growth and replication of viruses. These agents are used to treat viral infections by targeting specific stages of the viral life cycle or interfering with viral processes. It can be administered through various routes such as oral and intravenous. The different sectors include hospitals, clinics, research institutes, and others.

The COVID-19 (COVID-19) current therapy market covered in this report is segmented –

1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others

1) By Route Of Administration: Oral, Intravenous

2) By End-User: Hospitals, Clinics, Home Care, Others

The COVID-19 (COVID-19) current therapy market size has declined steeply in recent years. It will decline from $11.73 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of -50.0%. The decline in the historic period can be attributed to limited treatment options, varying treatment efficacy, supply chain disruptions, rapidly evolving scientific knowledge, emergence of variants.

The COVID-19 (COVID-19) current therapy market size is expected to see steep decline in the next few years. It will decline to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of -60.1%. The decline in the forecast period can be attributed to global vaccine rollout impact, long-term effects and chronic cases, regulatory and market access challenges, global economic factors. Major trends in the forecast period include investing in developing monoclonal antibody therapies, convalescent plasma therapies, cell-based therapies, and antiviral therapies, collaboration with government institutions and undergoing strategic partnerships with other pharmaceutical companies.

COVID-19 Pandemic Spurs Growth In The Global COVID-19 Current Therapy Market

The outbreak of the pandemic COVID-19 contributed to the growth of the COVID-19 (COVID-19) current therapy market. The World Health Organization (WHO) declared the outbreak a global pandemic. For instance, in August 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, the global COVID-19 cases reached 581.8 million. As there is no officially approved drug for COVID-19, the demand has risen significantly for repurposed drugs that are used for coronatherapy. Countries across the world are facing shortages of drugs, and drug manufacturers are ramping up production to meet the global demand. The COVID-19 Treatment Acceleration Program (CTAP) is a special emergency program initiated by the FDA for the development of potential COVID-19 therapies to be made available to patients as quickly as possible.

Healthcare Infrastructure Expansion Fueling Growth In The COVID-19 Current Therapy Market

The expansion of the healthcare infrastructure is expected to propel the growth of the COVID-19 (COVID-19) current therapy market going forward. The healthcare industry refers to amalgamating and integrating the economic system’s sectors that offer products and services for curing, preventing, rehabilitating, and providing palliative care for patients. Healthcare infrastructure is pivotal for the effective implementation of COVID-19 therapies, ensuring timely patient care, supporting research and clinical trials, and providing essential resources for optimal treatment delivery. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the US increased to 6,129 from 6,093 in 2022. Furthermore, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2020 and 2021, healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms. Therefore, the expansion of the healthcare industry is driving the growth of the COVID-19 (COVID-19) current therapy market.

Major companies operating in the COVID-19 (COVID-19) current therapy market report are Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals, Inc., Mylab Discovery Solutions, Kalbe Farma, He Qi Group Foundation, Beijing Jinwofu Bioengineering Technology Company, Zhejiang Orient Gene Biotech Co. Ltd., Transasia Bio Medicals, Vanguard Diagnostics, HLL Lifecare Limited, Voxtur Bio Ltd., Biocryst Pharma, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., LAB-CARE Diagnostics, ImmunoScience, CPC Diagnostics, Sysmex Corporation, Atomo Diagnostics, Cellmid Limited, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Hunan Lituo Biotechnology, Hangzhou Biotest Biotech, AmonMed Biotechnology, Getein Biotech, Beijing Tigsun Diagnostics, Vivacheck Lab, Seegene, SD Biosensor, Fujirebio, Siemens Healthcare Pte. Ltd., Senova, LetsGetChecked, Omega Diagnostics, Abingdon Health, Babylon, Motologic, F. Hoffmann-La Roche Ltd., Novacyt Group, AstraZeneca, Pfizer, Zentiva, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Amgen and Adaptive Biotechnologies, BioNtech, Cytodyn, Heat biologics, Johnson & Johnson, Takeda pharmaceuticals, Vaxart, Vir Biotechnology, Victory Square Health, Abbott Molecular Inc., ACRO Biotech, Advagen Biotech Ltd., BD, Boditech Med, Inc., Cellex Inc., CerTest Biotec, S.L., Hi Technologies, BATM, BioMedomics Quant Lease, CapeBio, Astel Diagnostics, Canary Health Technologies, Thermo Fisher Scientific

Challenges In Drug Development Process Pose Constraints On COVID-19 Current Therapy Market Growth

High costs involved in the research and development of therapeutic drugs and vaccines and the long waiting time required for each phase of clinical trials are expected to limit the growth of the COVID-19 (COVID-19) current therapy market. According to a recent study published in the Journal of Health Economics by the Tufts Center for the Study of Drug Development, it is estimated to cost $2.6 billion to develop a new prescription medicine and gain marketing approval, and seven out of eight pipeline drugs will fail in the development process. Moreover, the time required for each phase of the clinical trial and drug approval process takes an average of 12 years for an experimental drug to reach the market. High costs and long waiting times for drug development are expected to hamper the COVID-19 (COVID-19) current therapy market growth.

Exploring Convalescent Plasma Therapy As An Experimental Approach For COVID-19 Treatment

Convalescent Plasma Therapy is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent plasma therapy (CP) is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to a patient with severe disease to suppress virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection. According to guidance issued by the FDA, Convalescent Plasma Therapy is recommended as an investigational product during a public health emergency. Around 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, around 7,774 patients had enrolled, and 3,809 of them had undergone convalescent plasma transfusion. Experimental convalescent plasma therapy is likely to gain attention if enough data supports the results.

Innovation In COVID-19 Therapies On Oral Antiviral Treatments By Major Pharmaceutical Companies

Major companies operating in the COVID-19 (COVID-19) current therapy market are increasing their focus on introducing innovative products, such as COVID-19 oral antiviral treatment, to gain a competitive edge in the market. Antiviral treatment refers to the use of medications designed to inhibit the replication and spread of viruses within the body. For instance, in November 2021, Pfizer Inc., a US-based pharmaceutical company, launched PAXLOVID, a new oral antiviral candidate for COVID-19. The Phase 2/3 EPIC-HR study, evaluating the efficacy of PAXLOVID, revealed a consistent safety profile, making the product suitable for patients treated within three days of symptom onset. The interim analysis suggests that PAXLOVID has the potential to save lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations.

Clinical Trials Of Kevzara (Sarilumab) For COVID-19 Treatment With Collaboration Between Sanofi And Regeneron

In October 2021, Sanofi and Regeneron Pharmaceuticals planned to initiate clinical trials of the rheumatoid arthritis drug Kevzara (sarilumab) for the treatment of COVID-19 symptoms. The US Food and Drug Administration (FDA) approved Kevzara to treat rheumatoid arthritis. The drug is part of an ongoing antibody partnership between Sanofi and Regeneron. Kevzara is a fully human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only critical patients continue to be enrolled to receive Kevzara 400 mg.

North America is the largest region in the COVID-19 (COVID-19) current therapy market in 2023. Middle East is expected to be the fastest-growing region in the global COVID-19 (COVID-19) current therapy market share during the forecast period. The regions covered in the COVID-19 (COVID-19) current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the COVID-19 (COVID-19) current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The COVID-19 (COVID-19) current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The COVID-19 (COVID-19) current therapy market research report is one of a series of new reports from The Business Research Company that provides COVID-19 (COVID-19) current therapy market statistics, including COVID-19 (COVID-19) current therapy industry global market size, regional shares, competitors with a COVID-19 (COVID-19) current therapy market share, detailed COVID-19 (COVID-19) current therapy market segments, COVID-19 (COVID-19) current therapy market trends and opportunities, and any further data you may need to thrive in the COVID-19 (COVID-19) current therapy industry. This COVID-19 (COVID-19) current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

COVID-19 (COVID-19) Current Therapy Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $5.87 billion
Revenue Forecast In 2033 $0 billion
Growth Rate CAGR of -100% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others
2) By Route Of Administration: Oral, Intravenous
3) By End-User: Hospitals, Clinics, Home Care, Others
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Ipca Laboratories Limited; Zydus Cadila; Regeneron Pharmaceuticals, Inc.; Sun Pharmaceutical Industries Limited; AbbVie; Glenmark Pharmaceuticals Limited; Eli Lilly and Company; Wallace Pharmaceuticals, Inc.; Mylab Discovery Solutions; Kalbe Farma; He Qi Group Foundation; Beijing Jinwofu Bioengineering Technology Company; Zhejiang Orient Gene Biotech Co. Ltd; Transasia Bio Medicals; Vanguard Diagnostics; HLL Lifecare Limited; Voxtur Bio Ltd; Biocryst Pharma; Clover Biopharmaceuticals; Inovio Pharmaceuticals, Inc.; LAB-CARE Diagnostics; ImmunoScience; CPC Diagnostics; Sysmex Corporation; Atomo Diagnostics; Cellmid Limited; Moderna Therapeutics; Novavax; Bravovax; Ascletis Pharma; Altimmune; Hunan Lituo Biotechnology; Hangzhou Biotest Biotech; AmonMed Biotechnology; Getein Biotech; Beijing Tigsun Diagnostics; Vivacheck Lab; Seegene; SD Biosensor; Fujirebio; Siemens Healthcare Pte. Ltd.; Senova; LetsGetChecked; Omega Diagnostics; Abingdon Health; Babylon; Motologic; F. Hoffmann-La Roche Ltd.; Novacyt Group; AstraZeneca; Pfizer; Zentiva; Boehringer Ingelheim; GlaxoSmithKline; Merck & Co.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Sanofi; Amgen and AdaptiveBiotechnologies; BioNtech; Cytodyn; Heat biologics; Johnson&Johnson; Takeda pharmaceuticals; Vaxart; Vir Biotechnology; Victory Square Health; Abbott Molecular Inc.; ACRO Biotech; Advagen Biotech Ltd; BD; Boditech Med, Inc.; Cellex Inc.; CerTest Biotec, S.L.; Hi Technologies; BATM; BioMedomics Quant Lease; CapeBio; Astel Diagnostics; Canary Health Technologies; Thermo Fisher Scientific
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. COVID-19 (COVID-19) Current Therapy Market Characteristics

    3. COVID-19 (COVID-19) Current Therapy Market Trends And Strategies

    4. COVID-19 (COVID-19) Current Therapy Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global COVID-19 (COVID-19) Current Therapy Market Size and Growth

    5.1. Global COVID-19 (COVID-19) Current Therapy Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global COVID-19 (COVID-19) Current Therapy Historic Market Size and Growth, 2020 - 2023, Value ($ Billion)

    5.3. Global COVID-19 (COVID-19) Current Therapy Forecast Market Size and Growth, 2023 - 2024, 2025F, Value ($ Billion)

    6. COVID-19 (COVID-19) Current Therapy Market Segmentation

    6.1. Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    Remdesivir

    Hydroxychloroquine

    Ritonavir

    Lopinavir

    Interferon Beta

    Other Drug Type

    6.2. Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    Oral

    Intravenous

    6.3. Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    Hospitals

    Clinics

    Research Institutes

    Other End Users

    7. COVID-19 (COVID-19) Current Therapy Market Regional And Country Analysis

    7.1. Global COVID-19 (COVID-19) Current Therapy Market, Split By Region, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    7.2. Global COVID-19 (COVID-19) Current Therapy Market, Split By Country, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    8. Asia-Pacific COVID-19 (COVID-19) Current Therapy Market

    8.1. Asia-Pacific COVID-19 (COVID-19) Current Therapy Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    8.3. Asia-Pacific COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    8.4. Asia-Pacific COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    9. China COVID-19 (COVID-19) Current Therapy Market

    9.1. China COVID-19 (COVID-19) Current Therapy Market Overview

    9.2. China COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion

    9.3. China COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion

    9.4. China COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion

    10. India COVID-19 (COVID-19) Current Therapy Market

    10.1. India COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    10.2. India COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    10.3. India COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    11. Japan COVID-19 (COVID-19) Current Therapy Market

    11.1. Japan COVID-19 (COVID-19) Current Therapy Market Overview

    11.2. Japan COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    11.3. Japan COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    11.4. Japan COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    12. Australia COVID-19 (COVID-19) Current Therapy Market

    12.1. Australia COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    12.2. Australia COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    12.3. Australia COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    13. Indonesia COVID-19 (COVID-19) Current Therapy Market

    13.1. Indonesia COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    13.2. Indonesia COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    13.3. Indonesia COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    14. South Korea COVID-19 (COVID-19) Current Therapy Market

    14.1. South Korea COVID-19 (COVID-19) Current Therapy Market Overview

    14.2. South Korea COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    14.3. South Korea COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    14.4. South Korea COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    15. Western Europe COVID-19 (COVID-19) Current Therapy Market

    15.1. Western Europe COVID-19 (COVID-19) Current Therapy Market Overview

    15.2. Western Europe COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    15.3. Western Europe COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    15.4. Western Europe COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    16. UK COVID-19 (COVID-19) Current Therapy Market

    16.1. UK COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    16.2. UK COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    16.3. UK COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    17. Germany COVID-19 (COVID-19) Current Therapy Market

    17.1. Germany COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    17.2. Germany COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    17.3. Germany COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    18. France COVID-19 (COVID-19) Current Therapy Market

    18.1. France COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    18.2. France COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    18.3. France COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    19. Italy COVID-19 (COVID-19) Current Therapy Market

    19.1. Italy COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    19.2. Italy COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    19.3. Italy COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    20. Spain COVID-19 (COVID-19) Current Therapy Market

    20.1. Spain COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    20.2. Spain COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    20.3. Spain COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    21. Eastern Europe COVID-19 (COVID-19) Current Therapy Market

    21.1. Eastern Europe COVID-19 (COVID-19) Current Therapy Market Overview

    21.2. Eastern Europe COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    21.3. Eastern Europe COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    21.4. Eastern Europe COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    22. Russia COVID-19 (COVID-19) Current Therapy Market

    22.1. Russia COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    22.2. Russia COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    22.3. Russia COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    23. North America COVID-19 (COVID-19) Current Therapy Market

    23.1. North America COVID-19 (COVID-19) Current Therapy Market Overview

    23.2. North America COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    23.3. North America COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    23.4. North America COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    24. USA COVID-19 (COVID-19) Current Therapy Market

    24.1. USA COVID-19 (COVID-19) Current Therapy Market Overview

    24.2. USA COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    24.3. USA COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    24.4. USA COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    25. Canada COVID-19 (COVID-19) Current Therapy Market

    25.1. Canada COVID-19 (COVID-19) Current Therapy Market Overview

    25.2. Canada COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    25.3. Canada COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    25.4. Canada COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    26. South America COVID-19 (COVID-19) Current Therapy Market

    26.1. South America COVID-19 (COVID-19) Current Therapy Market Overview

    26.2. South America COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    26.3. South America COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    26.4. South America COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    27. Brazil COVID-19 (COVID-19) Current Therapy Market

    27.1. Brazil COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    27.2. Brazil COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    27.3. Brazil COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    28. Middle East COVID-19 (COVID-19) Current Therapy Market

    28.1. Middle East COVID-19 (COVID-19) Current Therapy Market Overview

    28.2. Middle East COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    28.3. Middle East COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    28.4. Middle East COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    29. Africa COVID-19 (COVID-19) Current Therapy Market

    29.1. Africa COVID-19 (COVID-19) Current Therapy Market Overview

    29.2. Africa COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    29.3. Africa COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    29.4. Africa COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

    30. COVID-19 (COVID-19) Current Therapy Market Competitive Landscape And Company Profiles

    30.1. COVID-19 (COVID-19) Current Therapy Market Competitive Landscape

    30.2. COVID-19 (COVID-19) Current Therapy Market Company Profiles

    30.2.1. Gilead Sciences, Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. F. Hoffmann-La Roche AG

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Ipca Laboratories Limited

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Zydus Cadila

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Regeneron Pharmaceuticals, Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. COVID-19 (COVID-19) Current Therapy Market Other Major And Innovative Companies

    31.1. Sun Pharmaceutical Industries Limited

    31.2. AbbVie

    31.3. Glenmark Pharmaceuticals Limited

    31.4. Eli Lilly and Company

    31.5. Wallace Pharmaceuticals, Inc.

    31.6. Mylab Discovery Solutions

    31.7. Kalbe Farma

    31.8. He Qi Group Foundation

    31.9. Beijing Jinwofu Bioengineering Technology Company

    31.10. Zhejiang Orient Gene Biotech Co. Ltd

    31.11. Transasia Bio Medicals

    31.12. Vanguard Diagnostics

    31.13. HLL Lifecare Limited

    31.14. Voxtur Bio Ltd

    31.15. Biocryst Pharma

    32. Global COVID-19 (COVID-19) Current Therapy Market Competitive Benchmarking

    33. Global COVID-19 (COVID-19) Current Therapy Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The COVID-19 (COVID-19) Current Therapy Market

    35. COVID-19 (COVID-19) Current Therapy Market Future Outlook and Potential Analysis

    35.1 COVID-19 (COVID-19) Current Therapy Market In 2024 - Countries Offering Most New Opportunities

    35.2 COVID-19 (COVID-19) Current Therapy Market In 2024 - Segments Offering Most New Opportunities

    35.3 COVID-19 (COVID-19) Current Therapy Market In 2024 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2020-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2024F, 2025F, $ Billion
  • Table 3: Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 4: Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 5: Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 6: Global COVID-19 (COVID-19) Current Therapy Market, Split By Region, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 7: Global COVID-19 (COVID-19) Current Therapy Market, Split By Country, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 8: Asia-Pacific, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 9: Asia-Pacific, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 10: Asia-Pacific, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 11: China, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 12: China, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 13: China, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 14: India, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 15: India, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 16: India, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 17: Japan, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 18: Japan, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 19: Japan, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 20: Australia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 21: Australia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 22: Australia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 23: Indonesia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 24: Indonesia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 25: Indonesia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 26: South Korea, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 27: South Korea, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 28: South Korea, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 29: Western Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 30: Western Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 31: Western Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 32: UK, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 33: UK, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 34: UK, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 35: Germany, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 36: Germany, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 37: Germany, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 38: France, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 39: France, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 40: France, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 41: Italy, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 42: Italy, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 43: Italy, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 44: Spain, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 45: Spain, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 46: Spain, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 47: Eastern Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 48: Eastern Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 49: Eastern Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 50: Russia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 51: Russia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 52: Russia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 53: North America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 54: North America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 55: North America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 56: USA, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 57: USA, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 58: USA, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 59: Canada, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 60: Canada, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 61: Canada, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 62: South America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 63: South America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 64: South America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 65: Brazil, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 66: Brazil, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 67: Brazil, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 68: Middle East, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 69: Middle East, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 70: Middle East, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 71: Africa, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 72: Africa, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 73: Africa, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Table 74: Gilead Sciences, Inc. Financial Performance
  • Table 75: F. Hoffmann-La Roche AG Financial Performance
  • Table 76: Ipca Laboratories Limited Financial Performance
  • Table 77: Zydus Cadila Financial Performance
  • Table 78: Regeneron Pharmaceuticals, Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2020-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2024F, 2025F, $ Billion
  • Figure 3: Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 4: Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 5: Global COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 6: Global COVID-19 (COVID-19) Current Therapy Market, Split By Region, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 7: Global COVID-19 (COVID-19) Current Therapy Market, Split By Country, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 8: Asia-Pacific, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 9: Asia-Pacific, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 10: Asia-Pacific, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 11: China, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 12: China, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 13: China, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 14: India, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 15: India, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 16: India, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 17: Japan, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 18: Japan, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 19: Japan, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 20: Australia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 21: Australia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 22: Australia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 23: Indonesia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 24: Indonesia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 25: Indonesia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 26: South Korea, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 27: South Korea, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 28: South Korea, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 29: Western Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 30: Western Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 31: Western Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 32: UK, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 33: UK, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 34: UK, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 35: Germany, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 36: Germany, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 37: Germany, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 38: France, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 39: France, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 40: France, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 41: Italy, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 42: Italy, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 43: Italy, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 44: Spain, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 45: Spain, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 46: Spain, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 47: Eastern Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 48: Eastern Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 49: Eastern Europe, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 50: Russia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 51: Russia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 52: Russia, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 53: North America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 54: North America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 55: North America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 56: USA, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 57: USA, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 58: USA, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 59: Canada, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 60: Canada, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 61: Canada, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 62: South America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 63: South America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 64: South America, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 65: Brazil, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 66: Brazil, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 67: Brazil, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 68: Middle East, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 69: Middle East, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 70: Middle East, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 71: Africa, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 72: Africa, COVID-19 (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 73: Africa, COVID-19 (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Figure 74: Gilead Sciences, Inc. Financial Performance
  • Figure 75: F. Hoffmann-La Roche AG Financial Performance
  • Figure 76: Ipca Laboratories Limited Financial Performance
  • Figure 77: Zydus Cadila Financial Performance
  • Figure 78: Regeneron Pharmaceuticals, Inc. Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
COVID-19 Rapid Test Kits Market 2022 – By Test Type (RT PCR Test, Rapid Antigen Test, Rapid Antibody Test, Others), By Test Components (PCR Machines, Equipment And Extraction Kits, Reagents), By Specimen Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab, Blood, Others), By End-Users (Hospitals And Clinics, Diagnostic Laboratories, Home Care, Others), And By Region, Opportunities And Strategies – Global Forecast To 2031
View Report
COVID-19 Rapid Test Kits Global Market Report 2024 – By Test Type (RT PCR Test, Rapid Antigen Test, Rapid Antibody Test, Others), By Test Components (PCR Machines, Equipment And Extraction Kits, Reagents), By Specimen Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab, Blood, Others), By End-Users (Hospitals And Clinics, Diagnostic Laboratories, Home Care, Others) – Market Size, Trends, And Global Forecast 2024-2025
View Report
DTP Vaccines Global Market Report 2024 – By Product type (DTaP, TD, Tdap), By Disease (Diphtheria, Pertussis, Tetanus), By End-User (Hospitals, Clinics, Vaccination Centers) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biologics Global Market Report 2024 – By Type (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), By Drug Classification (Branded Drugs, Generic Drugs), By Route Of Administration (Oral, Other Route Of Administration), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Hydroxychloroquine Global Market Report 2024 – By Drug Activity (Anti-Malarial Drug, Anti-Rheumatic Drug, Lupus Suppressant Drug, Anti COVID-19 Drug, Other Drug Activity), By Formulation (Tablets, Injection), By Application (Malaria, Rheumatoid Arthritis, Lupus Erythematosus, COVID-19, Other Applications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Specialty Drug Stores, Retail Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033
View Report
COVID-19 Detection Test Kits and Consumables Global Market Report 2024 – By Kits (Viral Load Testing Kits (qPCR and RT-PCR), Virus Neutralizing Assay Kits, Antibody Detection Kits (Elisa), Viral Antigen Detection Test Kits, Other Kits), By Consumables (Swabs, Tubes, Viral Transfer Media, Reagents, Other Consumables), By Specimen Type (Nose & Throat Swab, Blood, Sputum, Nasal Aspirate), By End Use (Hospitals, Clinics, Public Health Labs, Private And Commercial Labs, Physicians Labs, Research Institutes, Other End Uses) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Preventive Healthcare Technologies And Services Global Market Report 2024 – By Type (Early Detection and Screening Technologies, Vaccines, Chronic Disease Management Technologies, Advanced Technologies to Reduce Errors), By Application (Hospitals, Clinics) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pediatric Vaccine Market 2021 - By Vaccine Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Toxoid, Conjugate), By Application (Infectious Disease, Allergy, Cancer) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report

Frequently Asked Questions

What is the definition of the coronavirus (COVID-19) current therapy market?

Coronavirus (COVID-19) current therapy refers to a drug created and used to treat mild to moderate COVID-19 in those who have a higher risk of experiencing significant illness as a result of COVID-19. For further insights on the coronavirus (COVID-19) current therapy market, request a sample here

How will the coronavirus (COVID-19) current therapy market drivers and restraints affect the coronavirus (COVID-19) current therapy market dynamics? What forces will shape the coronavirus (COVID-19) current therapy industry going forward?

The coronavirus (COVID-19) current therapy market growth is aided by outbreak of the pandemic COVID-19. However, some coronavirus (COVID-19) current therapy market restraints include high costs involved in the research and development of therapeutic drugs and vaccines and the long waiting time required for each phase of clinical trials. For further insights on the coronavirus (COVID-19) current therapy market, request a sample here

What is the forecast market size or the forecast market value of the coronavirus (COVID-19) current therapy market?

The coronavirus (COVID-19) current therapy market is expected to reach $1.05 billion in 2027 at a rate of -45.3%. For further insights on the coronavirus (COVID-19) current therapy market, request a sample here

How is the coronavirus (COVID-19) current therapy market segmented?

The global coronavirus (COVID-19) current therapy market is segmented as
1) By Drug Type: Remdesivir, Hydroxychloroquine, Ritonavir, Lopinavir, Interferon Beta, Other Drug Type
2) By Route Of Administration: Oral, Intravenous
3) By End User: Hospitals, Clinics, Research Institutes, Other End Users
For further insights on the coronavirus (COVID-19) current therapy market, request a sample here

Which region has the largest share of the coronavirus (COVID-19) current therapy market? What are the largest region's market size and growth rate?

North America was the largest region in the coronavirus (COVID-19) current therapy market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the coronavirus (COVID-19) current therapy market?

Key competitors in the coronavirus (COVID-19) current therapy market are, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Clover Biopharmaceuticals, Inovio Pharmaceuticals Inc., Biocryst Pharma, Gilead Sciences, Regeneron Pharmaceuticals, Applied DNA Sciences Inc, Codagenix, GeoVax Labs Inc., Takis Biotech, Evvivax, Zydus Cadila, MIGAL Galilee Research Institute, Generex Biotechnology Corporation, Janssen Pharmaceuticals, Greffex Inc., CanSino Biologics Inc., ExpreS2ion Biotechnologies ApS, Vaxil Bio Ltd., iBio Pharma Inc, Tonix Pharmaceuticals, Curevac, ImmunoPrecise, AbbVie, AbCellera / Eli Lilly, Stemirna Therapeutics. For further insights on the coronavirus (COVID-19) current therapy market, request a sample here.

What are the key trends in the coronavirus (COVID-19) current therapy market?

Major trends influencing the coronavirus (COVID-19) current therapy market include convalescent plasma therapy which is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent plasma therapy (CP) is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to a patient with severe disease in order to suppress virulence and improve clinical symptoms.The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection. For further insights on the coronavirus (COVID-19) current therapy market, request a sample here.

What are the major opportunities in the coronavirus (COVID-19) current therapy market? What are the strategies for the coronavirus (COVID-19) current therapy market?

For detailed insights on the major opportunities and strategies in the coronavirus (COVID-19) current therapy market, request a sample here.

How does the coronavirus (COVID-19) current therapy market relate to the overall economy and other similar markets?

For detailed insights on coronavirus (COVID-19) current therapy market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the coronavirus (COVID-19) current therapy industry?

For detailed insights on the mergers and acquisitions in the coronavirus (COVID-19) current therapy industry, request a sample here.

What are the key dynamics influencing the coronavirus (COVID-19) current therapy market growth? SWOT analysis of the coronavirus (COVID-19) current therapy market.

For detailed insights on the key dynamics influencing the coronavirus (COVID-19) current therapy market growth and SWOT analysis of the coronavirus (COVID-19) current therapy industry, request a sample here.